Yanan Zhu
Stock Analyst at Wells Fargo
(4.44)
# 1,216
Out of 5,152 analysts
478
Total ratings
35.4%
Success rate
11.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RNA Atrium Therapeutics | Rated: Buy | $25 | $6.64 | +276.51% | 5 | Nov 16, 2026 | |
| STRO Sutro Biopharma | Rated: Buy | $49 | $8.50 | +476.47% | 2 | Nov 16, 2026 | |
| PHVS Pharvaris | Rated: Buy | $65 | $31.55 | +106.02% | 5 | Nov 13, 2026 | |
| SCTX Scribe Therapeutics | Rated: Buy | $60 | $14.05 | +327.05% | 3 | Nov 13, 2026 | |
| ENGN enGene Therapeutics | Upgraded: Buy | $2 → $6 | $1.85 | +224.32% | 21 | Nov 12, 2026 | |
| MGX Metagenomi Therapeutics | Reiterated: Buy | $7 | $0.6318 | +1,007.95% | 16 | Nov 11, 2026 | |
| ZNTL Zentalis Pharmaceuticals | Reiterated: Hold | $5 | $1.36 | +267.65% | 2 | Nov 11, 2026 | |
| IONS Ionis Pharmaceuticals | Rated: Buy | $95 → $80 | $27.39 | +192.08% | 47 | Nov 10, 2026 | |
| EDIT Editas Medicine | Reiterated: Buy | $6 | $1.77 | +238.98% | 27 | Nov 9, 2026 | |
| ARCT Arcturus Therapeutics Holdings | Reiterated: Buy | $20 | $8.04 | +148.76% | 28 | Nov 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $3.5 → $3 | $1.05 | +185.71% | 14 | Nov 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $400 → $435 | $403.60 | +7.78% | 4 | Nov 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $38 | $14.53 | +161.53% | 18 | Nov 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $105 | $51.32 | +104.60% | 4 | Nov 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $55 | $19.74 | +178.62% | 6 | Nov 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $75 | $20.30 | +269.46% | 30 | Nov 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $115 | $101.46 | +13.35% | 18 | Nov 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $70 | $21.01 | +233.17% | 25 | Nov 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $75 → $70 | $40.19 | +74.17% | 18 | Nov 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $7.48 | +140.64% | 29 | Oct 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $87 → $110 | $95.05 | +15.73% | 2 | Oct 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $102 | $78.01 | +30.75% | 1 | Oct 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $15 | $9.77 | +53.53% | 27 | Oct 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.11 | - | 22 | Jun 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 | $3.99 | +175.69% | 28 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $1.06 | +371.70% | 19 | Jan 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $4 | $1.03 | +288.35% | 9 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1.5 → $1 | $0.0235 | n/a | 11 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $11 → $0.1 | $0.0001 | n/a | 11 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $1.67 | n/a | 13 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $21.04 | n/a | 7 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $45 → $30 | $1.72 | n/a | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $272 → $326 | $941.25 | n/a | 4 | Feb 2, 2021 |
Atrium Therapeutics
Nov 16, 2026
Rated: Buy
Price Target: $25
Current: $6.64
Upside: +276.51%
Sutro Biopharma
Nov 16, 2026
Rated: Buy
Price Target: $49
Current: $8.50
Upside: +476.47%
Pharvaris
Nov 13, 2026
Rated: Buy
Price Target: $65
Current: $31.55
Upside: +106.02%
Scribe Therapeutics
Nov 13, 2026
Rated: Buy
Price Target: $60
Current: $14.05
Upside: +327.05%
enGene Therapeutics
Nov 12, 2026
Upgraded: Buy
Price Target: $2 → $6
Current: $1.85
Upside: +224.32%
Metagenomi Therapeutics
Nov 11, 2026
Reiterated: Buy
Price Target: $7
Current: $0.6318
Upside: +1,007.95%
Zentalis Pharmaceuticals
Nov 11, 2026
Reiterated: Hold
Price Target: $5
Current: $1.36
Upside: +267.65%
Ionis Pharmaceuticals
Nov 10, 2026
Rated: Buy
Price Target: $95 → $80
Current: $27.39
Upside: +192.08%
Editas Medicine
Nov 9, 2026
Reiterated: Buy
Price Target: $6
Current: $1.77
Upside: +238.98%
Arcturus Therapeutics Holdings
Nov 6, 2026
Reiterated: Buy
Price Target: $20
Current: $8.04
Upside: +148.76%
Nov 6, 2026
Rated: Hold
Price Target: $3.5 → $3
Current: $1.05
Upside: +185.71%
Nov 6, 2026
Rated: Buy
Price Target: $400 → $435
Current: $403.60
Upside: +7.78%
Nov 6, 2026
Reiterated: Buy
Price Target: $38
Current: $14.53
Upside: +161.53%
Nov 5, 2026
Reiterated: Buy
Price Target: $105
Current: $51.32
Upside: +104.60%
Nov 5, 2026
Reiterated: Buy
Price Target: $55
Current: $19.74
Upside: +178.62%
Nov 5, 2026
Reiterated: Buy
Price Target: $75
Current: $20.30
Upside: +269.46%
Nov 5, 2026
Rated: Buy
Price Target: $115
Current: $101.46
Upside: +13.35%
Nov 4, 2026
Rated: Buy
Price Target: $70
Current: $21.01
Upside: +233.17%
Nov 4, 2026
Rated: Hold
Price Target: $75 → $70
Current: $40.19
Upside: +74.17%
Oct 29, 2026
Reiterated: Buy
Price Target: $18
Current: $7.48
Upside: +140.64%
Oct 28, 2026
Reiterated: Buy
Price Target: $87 → $110
Current: $95.05
Upside: +15.73%
Oct 15, 2026
Reiterated: Buy
Price Target: $102
Current: $78.01
Upside: +30.75%
Oct 2, 2026
Reiterated: Hold
Price Target: $15
Current: $9.77
Upside: +53.53%
Jun 25, 2026
Rated: Hold
Price Target: n/a
Current: $0.11
Upside: -
May 7, 2026
Reiterated: Buy
Price Target: $11
Current: $3.99
Upside: +175.69%
Jan 14, 2026
Reiterated: Buy
Price Target: $5
Current: $1.06
Upside: +371.70%
Jan 13, 2026
Reiterated: Hold
Price Target: $4
Current: $1.03
Upside: +288.35%
May 14, 2025
Reiterated: Hold
Price Target: $1.5 → $1
Current: $0.0235
Upside: n/a
May 14, 2025
Downgraded: Hold
Price Target: $11 → $0.1
Current: $0.0001
Upside: n/a
May 6, 2025
Reiterated: Buy
Price Target: $10
Current: $1.67
Upside: n/a
May 16, 2024
Rated: Hold
Price Target: n/a
Current: $21.04
Upside: n/a
Aug 16, 2023
Reiterated: Hold
Price Target: $45 → $30
Current: $1.72
Upside: n/a
Feb 2, 2021
Reiterated: Hold
Price Target: $272 → $326
Current: $941.25
Upside: n/a